Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q2 2021 · 10-Q
Revenue$715.93M$715.93M+33.4% vs Q2 2020 Net Income$916.80M$916.80M−5.1% vs Q2 2020 EPS Diluted$30.41$30.41−5.4% vs Q2 2020 Gross Profit$401,100,000+36.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$154,624,000+67.8% Free Cash Flowderived$131,236,000+77.3% Margins · derivedGross margin56.0%+1.5 pt vs Q2 2020
Operating margin17.4%+7.8 pt vs Q2 2020
Net margin128.1%
ended Jun 30, 2021 · filed Jul 30, 2021 · 30 d after period end